According to Article 102 of the Drug Administration Law of the People's Republic of China, drugs are defined as substances used for the prevention, treatment and diagnosis of human diseases, the purposeful regulation of human physiological functions and the stipulation of indications or functions, usage and dosage, including Chinese herbal medicines, Chinese medicinal herbs, Chinese medicinal tablets, proprietary Chinese medicines, chemical raw materials and their preparations, antibiotics, biochemical drugs, radioactive drugs, serums, vaccines, blood products and diagnostic drugs. medicines, serums, vaccines, blood products and diagnostic drugs, etc. In January 2013, the National Development and Reform Commission (NDRC) issued a circular deciding to adjust the maximum retail price limits for respiratory, antipyretic and analgesic and specialty special drugs from February 1, 2013,*** involving 20 categories of medicines, more than 400 varieties, more than 700 representative dosage specifications, with an average reduction of 15%, of which the average reduction of high-priced medicines amounted to 20%. The average price reduction of the drugs reached 20%.
Chinese name
Drugs
Foreign name
medicien
According to
"Chinese People's Republic of China
and the State Drug Administration Law"Role
Preventing, treating, and diagnosing human illnesses
Includes
Chinese herbs, and Chinese herbal medicines and drinking tablets, Chinese patent medicines
Varieties
More than 400 varieties
1 Characteristics Introduction Edit
From the object of use: it is to be used by human beings, preventing, treating, and diagnosing human diseases. Purposeful regulation of human physiological functions, there are provisions
applications, usage and dosage requirements; from the method of use: in addition to the appearance, the patient can not recognize its internal quality, many drugs need to be used under the guidance of a doctor, rather than by the patient's choice to decide. At the same time, the use of drugs, quantity, time and other factors to a large extent to determine the effect of its use, misuse not only can not "cure", but also may "cause disease", and even endanger the safety of life. Therefore, medicine is a special commodity.
1. Complexity of types: specific varieties, the world has about 20,000 kinds, China's traditional Chinese medicine preparations of about 5,000 kinds, about 4,000 kinds of Western medicine preparations, which can be seen, the complexity of the types of medicines, a wide range of varieties.
2. The medical exclusivity of medicines: medicines are not an independent commodity, it is closely integrated with medicine, complementary. Patients only through the doctor's examination and diagnosis, and under the guidance of the doctor's reasonable use of medicines, in order to achieve the purpose of preventing disease and protecting health.
3. Strictness of the quality of medicines: medicines are directly related to people's health and even the survival of life, therefore, its quality must not be sloppy. We must ensure that the drugs are safe, effective, uniform and stable.
Additionally, the quality of medicines has significant characteristics: it is not like other commodities, there are quality levels: superior, first-class, second-class, qualified products, etc., can be sold, while the drugs are only in line with the provisions of the regulations and non-compliance with the provisions of the points, only in line with the provisions of the product can be permitted to sell, or shall not be sold.
2 Management Standards Editor
Drug quality compliance is not only the product quality in line with the registered quality standards, but also to make the whole process in line with the "Good Manufacturing Practice" (referred to as GMP).
"Good Manufacture Practice" (GMP) is a basic guideline for drug production and quality management, applicable to the whole process of drug preparation production and the production of raw materials affecting the quality of the finished product of the key processes. The vigorous implementation of GMP is to maximize the avoidance of contamination and cross-contamination in the process of drug production, reduce the occurrence of various errors, is an important measure to improve the quality of drugs.
3Price Reduction Editor
In early January 2013, the National Development and Reform Commission issued a notice deciding to adjust the maximum retail price limit for respiratory, antipyretic and analgesic and specialty special drugs and other medicines as of February 1, 2013,*** involving 20 categories of medicines, more than 400 varieties and 700 representative dosage form specifications, with an average price reduction of 15%, among which the average reduction rate of high-priced The average price reduction of drugs reached 20%. [1]
The earliest health insurance varieties average price reduction of 40%
According to the National Development and Reform Commission price division of the relevant person in charge of the scope of government pricing of medicines (mainly medicare catalog drugs), the Development and Reform Commission based on the cost of medicines and the market price changes in the situation and other factors, the implementation of the price of the dynamic adjustment mechanism, generally adjusted once in 2-3 years. Since 2001, the NDRC has issued three rounds of drug price adjustment programs, involving nearly 2,000 types of drugs. The earliest varieties into the medical insurance catalog, the cumulative price reduction has reached an average of 40%, the high reached 80%; the latest varieties into the medical insurance catalog, the price reduction has just begun, an average of about 15%. [1]
The first round of adjustments, from 2001 to 2003, saw the first comprehensive adjustment of government-managed price medicines. [1]
The second round of adjustments from 2006 to 2007 combined with varieties of medical insurance catalogs to once again make comprehensive adjustments to government-managed price medicines. [1]
From 2011 to 2012, the NDRC carried out a comprehensive adjustment of the government-managed price of chemical drugs. [1]
The eight categories of drugs that have been adjusted in four batches since 2011, including antibiotics, circulatory, neurological, hormonal, digestive, antitumor, immune and blood, belong to the same round of price adjustment varieties, and most of them belong to the commonly used clinical drugs. So far, the NDRC price adjustment of chemical drugs is basically completed, from 2013, will start the adjustment of the price of proprietary Chinese medicines. [1]
Appropriate price increases for low-priced drugs in clinical shortage
According to the tracking and investigation of previous drug price adjustments by the relevant departments of the National Development and Reform Commission (NDRC), the drug price adjustments have had an obvious effect of reducing the burden of patients who use medicines on a regular basis. The latest round of drug price reductions can reduce the burden on patients by more than 60 billion yuan a year. This round of price adjustments of high-priced drugs by an average of 20%. For example, the treatment of Alzheimer's disease (dementia) carboplatin capsules 1.5 mg × 28 tablets (produced by Novartis, the trade name of "Aisnen"), the daily cost of 32.6 yuan before the price cuts, after the price cuts, the daily cost of 19.8 yuan, a 39% reduction. [1]
At the same time, the price adjustment of drugs has also played a positive role in the production structure of enterprises. The relevant person in charge of the National Development and Reform Commission said that the media reflected the part of the drug "price reduction death" problem, the investigation found that, in addition to the short-term off the shelves, there are a very small number of drugs due to poor business operations, low market utilization of the product and other reasons to withdraw from the market, but did not find just because of the reduction of the price of the disappearance of the situation. This time, while reducing the prices of high-priced medicines and alleviating the burden of medicines on the public, the State has also focused on strengthening price support for low-priced medicines. In particular, for low-priced drugs in clinical shortage, the National Development and Reform Commission (NDRC) has appropriately raised the prices on the basis of cost and price surveys, expert evaluation and extensive listening to the opinions of relevant parties, in order to encourage the production and supply of low-priced drugs to meet clinical needs. [1]
4MissionEdit
Mission of pharmaceutical people: to guarantee the safety, effectiveness, homogeneity and stability of drugs.
Firstly, social justice***ness. Human biological endowment has been prompting human beings to enhance health and prolong life as much as possible to ensure human reproduction. Pharmaceuticals are highly valued for their special effects. In modern society, the right to health and the right to life have become basic human rights protected by law. Therefore, medicines are related to the reproduction and development of the whole human society. The social public ****ness of medicines is the basis for the establishment of a universal health care and medical insurance system.
Secondly, the dual role. Drugs can prevent and cure diseases, rehabilitation and health care, however, "medicine is three times poisonous", any drug has different degrees of toxic side effects. So the management of a square, with the right, the drugs can cure the disease, protect health. On the contrary, it will degenerate into a horrible poison, endangering human health and life safety.
Third, the quality of a single. The physical, chemical, biological pharmacology, safety, effectiveness, stability, homogeneity and other quality indicators of drugs must meet the national standards. Only medicines that meet national standards can guarantee efficacy. Lower or higher quality standards may reduce or even lose the efficacy of the drug or aggravate the toxicity or side effects of the drug. Therefore, the drugs entering the distribution channel are only allowed to have qualified products, and absolutely not allowed to have inferior or inferior products.
Fourth, the identification of professionalism. The advantages and disadvantages of the quality of drugs, authenticity, general consumers are difficult to identify. There must be professional and technical personnel and specialized agencies, based on the statutory standards, the use of scientific methods and qualified equipment, in order to make the identification.
Fifth, the limitations of the application. Due to the lack of professional medical and pharmaceutical knowledge required to treat and prevent diseases, people in most cases can only be under the guidance of licensed physicians and pharmacists, and even under the supervision of health care personnel, in order to rationalize the use of drugs, to achieve the prevention and treatment of disease, health protection purposes. If drugs are abused, they can easily cause poisoning or drug-induced diseases. In addition, when people are sick, sometimes they need a little more medication.
5Classification Editor
Drugs are categorized according to their uses, including cold medicine, antipyretic, stomach medicine, laxative, hypnotic and other kinds of medicines conducive to good health, and according to the nature of the classification, including traditional Chinese medicines, Chinese herbal medicines, Chinese medicinal herbs, proprietary Chinese medicines, Chinese and Western proprietary Chinese medicines, chemical raw materials and their preparation, antibiotics, biochemical medicines, radiopharmaceuticals, serums, vaccines, blood products and diagnostic medicines, and so on.
6Export Prospects Edit
China will overtake India as the most popular place for international drug purchases in 2010.
China's exports of APIs and active pharmaceutical ingredients are expected to grow from $5.63 billion in 2007 to $9.9 billion in 2010, while India will grow from $1.7 billion in 2007 to $2.76 billion in 2010.
China's exports of these products mainly include antibiotics, vitamins, amino acids and organic acids, with major markets including the European Union, the United States, India and Japan. India will continue to lead in finished drug exports, which are expected to grow from $4.8 billion in 2007 to $6.4 billion in 2010, while China will grow from $700 million in 2007 to $1.88 billion in 2010.
In the international purchasing market, China is ranked first, India second, and South Korea third in terms of the popularity of outsourcing pharmaceuticals, combining indicators such as cost, market opportunity, and risk factors. Although India's drug exports exceed China's, China has taken the lead in exports of APIs and active ingredients of drugs.
7 Development Status Edit
"The domestic new drug research and development enthusiasm, a large number of personnel, urgent needs, a broad market plus the government's attention, it can be said that the opportunities are frequent, but the status quo is not optimistic." At the fourth China International Biomedical Development Summit, such a viewpoint is very representative.
1. New drugs are hard to find, generic drugs are hard to imitate
"The existing R&D model and process are getting harder and harder to discover new drugs. On the basis of existing life sciences and technology, after rounds and rounds of screening, almost all known biochemical molecular reactions and biochemical enzyme reactions have been developed by the pharmaceutical industry." said John Duan, senior review officer and clinical pharmacologist at the FDA.
The clichés about drug innovation, such as lower output rates of new drugs, rising R&D costs, long clinical times and slow time-to-market ......, still persist, and the sustainability of domestic biopharmaceutical development is difficult because of its own weak foundation and lack of accumulation.
The biopharmaceutical industry has been growing at a faster rate than the overall pharmaceutical industry, but domestic biopharmaceutical technology still has a considerable gap with developed countries, and the scale of biopharmaceutical companies is much smaller than that of chemical companies. And domestic chemical drugs have been taking the "me to (generic) - me better (better generic) - me new (innovation)" route, which is not easy for biological drugs. The reason is that it is difficult to determine the bioequivalence of biosimilars.
In fact, the manufacturing process differs greatly between chemical and biological drugs. Chemical drugs are simple, small-molecule compounds that can be easily produced in a similar structure by controlling the chemical formulation, and at the same time, laboratory tests can be used to confirm whether the generic drug has the same efficacy as the original patented product. However, the case of biologics is completely different, as a small difference in the moiety can lead to very different effects. As a result, it is very difficult for biosimilars to gain regulatory approval in either the U.S. or China. And the cost and time involved in proving bioequivalence in large-scale clinical trials can be substantial.
Jin Gang, senior vice president of Shanghai Biochip, analyzed that biopharmaceuticals themselves are already a high-investment, high-risk industry. Generic drugs do not have patent protection, spend a lot of effort to do clinical trials, the result is that the market is not protected, it is easy to be copied by other competitors, profits quickly reduced. Therefore, in the United States, no venture capitalists are willing to accept drugs without patents. Even with complete patent protection, there is still a long way between patented technology and marketable products, and even many patents themselves do not have the possibility of being marketed or the target market is too small to be marketable. In other words, the products developed must not only be biologically druggable, but also have full patent protection.
2. Funding and technology are not fully docked
Returning to China for more than a year, Dr. Zhang Lei, a doctor of immunology and medicine, found that some of the phenomena make him very confused: domestic R & D institutions and some biological companies are very poor, and R & D and transformation of the results is very difficult; at the same time, the investment companies do not dare to invest easily because of the investment cycle is too long, do not see a clear prospect, and can not find a home, and other reasons.
In fact, due to the high growth of the pharmaceutical industry, there are a lot of money around the pharmaceutical spin, but it is understood that the domestic biomedicine to attract funds only accounted for the entire pharmaceutical financing about 5% of the share. In addition, the general financial investment is mostly hope that a short period of time to see the benefits, and a drug to be listed is a need a long time to see the results, even if the market, the subsequent risk still exists. Comparatively speaking, strategic investment is more focused on long-term benefits, and can take several years to finance and help companies do strategic planning, management optimization and so on.
Li Yi, a partner at Biovida China Fund, said there are still many investment opportunities in the pharmaceutical industry, and as a professional investment firm, they may choose early-stage companies with breakthrough platform technologies or huge markets, even if they are very small or require a long time to return on investment, as long as the companies have an efficient and collaborative management team, independent products, and significant competitive advantages, clear market opportunities and sustainable business models, investment companies are willing to accept them.
There are not many domestic companies that can meet the above criteria. In addition, because the upstream and downstream dependence chain has not been established, many domestic enterprises are simply R&D-led, and then transfer the project, lacking long-term strategic positioning and market considerations.
"China actually does not lack of biological R & D talents, but there is no enterprise-oriented innovation system, and there is no venture capital market, China's biomedical industry has great potential, but the model is unclear." An industry insider commented.
3. Finding the fire for biopharmaceuticals
Zhang Invention, president of Sino-US Guanke Biotechnology (Beijing) Co., Ltd, believes that once upon a time our R&D model was to take a magnifying glass to look for a needle in a pile of firewood to cure a disease, and we need to set a fire to burn off the unneeded firewood, and then what's left behind is the needle. In new drug development, biomarkers are the match that burns the straw.
The so-called biomarkers are researched through the knowledge of genomics and oncology to find those biochemical indicators that can be objectively measured and evaluated as a characteristic of a general physiological or pathological or therapeutic process, through which one can be informed of the process in the biological process in which the organism is currently engaged.
In fact, this is a shift in R&D thinking, John Duan said, adding that the conventional approach to new drug research is to carry out basic research, then discover pharmacologically active compounds from a large library of compound samples, and then carry out steps such as optimization of the chemical structure and design, preclinical research, and clinical trials. Usually less than 1 compound with pharmacological activity is screened from 10,000 compounds, and even fewer reach clinical trials. The shift can be to start with disease research, study the principle of the disease itself, figure out the most influential regions, and target them with targeted research and screening. "Better target identification capabilities will not only improve the efficiency of screening for lead compounds, but will also allow for a more precise determination of drug effectiveness in the early clinical research phase.
"Be discerning in selecting projects, be clear about whether the R&D product has a sufficiently sized market, and how long the cycle of elimination of such drugs is, so don't learn the art of slaying the dragon and end up not being able to find the dragon at all." Participants described.
One organization predicted that by 2010, China will become the world's seventh largest pharmaceutical market, Chinese national demand in the field of health has a huge growth force. Biomedicine because of its specificity, accuracy and other characteristics, there are still many areas of research can be carried out. China's biopharmaceuticals are still in the early stage of the industry and need a long time to cultivate.
8Fake DrugsIntroductionEdit
Drugs(5pictures)
Fake Drugs (Bogus Drug) in accordance with the People's Republic of China **** and the State Drug Administration Law, Article 48: prohibit the production (including preparation, the same below), the sale of fake drugs.
The following circumstances, for fake drugs:
(a) the composition of the drug does not match the composition of the national drug standards;
(b) non-drugs as drugs or other kinds of drugs as such drugs.
Drugs in one of the following circumstances shall be punished as counterfeit drugs:
(1) those whose use is prohibited by the State Council's Drug Administration;
(2) those which must be approved in accordance with this Law, but which have not been approved for production or importation, or those which must be inspected in accordance with this Law but which have been sold without inspection;
(3) those which have been deteriorated;
(4) those which have been contaminated.
(e) the use of raw materials in accordance with this Law must obtain an approval number but did not obtain the approval number of the production;
(f) labeled indications or functions beyond the scope of the provisions of the main.
Supplementary
Star endorsement of drugs will be held criminally liable if they are known to be fake, Xiong Xanguo, vice president of the Supreme People's Court, pointed out at a news conference held by the State Council Information Office, noting that celebrities will be held criminally liable for endorsement of drugs if they are known to be fake.
Xiong Xuanguo said, referring to the behavior of celebrity endorsement, from the point of view of judicial interpretation, first of all, or to provide advertising and promotion of such a behavior of the positioning of the problem. According to the provisions of the Criminal Law, the production and sale of counterfeit drugs, substandard drugs crime, is an intentional crime, constitute **** crime is to know or should know that others produce, sell counterfeit drugs, substandard drugs as a prerequisite. So for the star's endorsement behavior, if he is aware of others to produce, sell counterfeit drugs, substandard drugs, in line with the provisions of the Criminal Law, as a *** offender can be dealt with, but this premise is very important.
It is understood that on May 13, 2009, the Supreme People's Court, the Supreme People's Procuratorate co-signed the "on the handling of the production and sale of counterfeit medicines, substandard medicines criminal cases of specific application of the law on a number of issues of the Interpretation", will be implemented on May 27, 2009 onwards. The Interpretation clarifies some difficult issues in the application of law in handling criminal cases of production and sale of counterfeit and substandard drugs.
Avoiding fake drugs
First step: choose a regular pharmacy network
Consumers have to recognize the authenticity of the information, first of all, to the legal, regular pharmacy network to buy. Statistics show that as of November 15, 2010, the country *** there are 2,588 legitimate websites that provide information on pharmaceutical services, of which 54 are involved in pharmaceutical transactions. Of these 54 websites providing drug transaction services, only 33 have legal qualifications to sell drugs to individuals. Choosing a regular pharmacy network is an important step to avoid buying fake drugs.
The second step: how to identify drugs
The appearance of the drugs mentioned in the appearance identification techniques has two meanings: one is the appearance of the drug packaging, including the box, box, bottle, labeling, manuals, and other items, and the other is the appearance of the shape of the drug itself.
Through the appearance of the inspection of identification methods to determine whether the inspection of fake and shoddy drugs, should pay attention to the following issues:
1. Identification of the most basic technical basis for comparison
This is established in the real and fake products against the comparison of the basis of a method, and therefore, the drug inspectors should be aware of the familiar with a variety of regular manufacturers of the appearance of the product, which requires us to accumulate experience during the usual inspection work. This requires us to accumulate experience in the usual inspection work, and constantly improve the level of identification.
2. Check the source channels of drugs
In the process of checking the drugs, we should review the source documents of various drugs, and cautiously recognize the authenticity of the shipping documents, and strengthen the inspection of the relevant situation, the production of counterfeit and inferior medicines, the sales channels and the regular products are obviously different.
3. Check the price of drugs
The sales price of fake and shoddy drugs is generally significantly lower than the price of genuine products, and some are even lower than the cost of the product, in the supervision and inspection of medicines, if you find that the price of a drug is significantly lower than the cost of the price or deviation from the cost of attention should be drawn to the timely sampling and testing.
4. Drug counterfeiting is also a rule of thumb
Best-selling varieties, varieties in short supply, well-known brands, expensive drugs are often the object of counterfeiting, and the phenomenon of false adulteration also occurs, the means of counterfeiting in the constant change, drug inspectors should be flexible in response to the actual situation.
5. The appearance of drugs identification of the scene is very strong
So the method and the basic environment is also subject to certain restrictions, in the conditions allow, should try to carry out experiments with a rapid test identification method, to draw further conclusions, such as thin-layer chromatography and chemical reaction identification method.
Identifying the real
Simple identification methods:
I. It is to look at the approval number on the package.
1. Drugs on the package must be able to see the approval number: "State Drug Permit H (or Z.S.J.B.F) + 8 digits", which means that the State Drug Administration approved the production of medicines, listed for sale, the letter H on behalf of the chemical drugs, Z proprietary Chinese medicines, S biologics, J imported medicines in domestic sub-packaging, B drugs with auxiliary therapeutic effects, F medicinal excipients.
2. If there is no "State Drug Certification" on the package is certainly not a drug, if there is "State Drug Certification" log on to the State Drug Administration data query, enter the name of the drug or "State Drug Certification", "State Drug Certification". "behind the letters and 8 numbers, check the real drug, can not check is a fake drug.
3. If the approval number is: X drug preparation word H (Z) + 4 years + 4 running number, such an approval number is a hospital preparation, can only be used in this hospital, can not be sold in other hospitals and pharmacies.
4. If the expiration date is not indicated or changed on the package of the drug, and if the production lot number is not indicated or changed, and if it exceeds the expiration date, it is an inferior drug.
5. The identification of health food and food.
(1). Health food in the package must be able to see the State Drug Administration's approval number: State Food and Health word G (J) +8 for the number, the letter G refers to domestic J refers to imported. Or the approval number of the Ministry of Health: Wei Food Jian Zi (Wei Food Jian Jin Zi) + 8 digits. And the provisions of the packaging or labeling must be marked on the top of the special identification of health products: "blue hat", a pattern similar to the blue hat, below the four words of health food, health food four words below is the approval number. There is no blue hat and health food approval number is fake health products.
(2). Food in the package marked with "food production license number" are to QS beginning with the back of the 12-digit running number. There is a "health license number" to the provinces of the abbreviation of the beginning of the back is the running number, such as Yu Wei food license word, Guangdong Wei food license word, Shanghai Wei food license word, etc., it is a rectangular logo in a white background with a deformed blue Q word with a white S. Called the QS logo, QS below the quality and safety of the four words.
6. Identify the drugs to see if there is an approval number: "State Drug Approval", there is a State Drug Approval, on the landing of the State Drug Administration database, can not be found is a fake drug. Buy health care products to see: there is no blue hat and the state's approval number, you can also log on to the State Drug Administration database, can not be found is a fake health care products. Buy food to see if there is a QS logo and food production license number.
Complicated identification methods: professional organizations (Drug Inspection Institute) through chemical, physical and other testing methods in order to determine the authenticity of drugs.
9 storage principles editor
1. Performance of each other, easy to crosstalk, the name is easy to get the wrong species should also be stored separately.
2. Narcotic drugs, psychotropic drugs, toxic drugs should be stored in a special library or special cabinet, and designate a person for safekeeping.
3, dangerous goods should be strictly enforced by the Ministry of Public Security issued the "Interim Measures for the Management of Chemical Dangerous Goods Storage", "Explosives Management Rules" and "Warehouse Fire Safety Management Rules "and other provisions, according to its dangerous nature, categorized and stored in a special warehouse with specialized facilities.
4, effective drugs according to the validity of the near and far, according to the batch number, in order to specialize in stacking. And according to the "China Pharmaceutical Company, pharmaceutical commodities transfer responsibility system" stipulates the period of time, regularly report to the business sector in time to sell.
5, long-term storage of goods afraid of pressure regularly turn the whole stack, the stacks should take the necessary measures to separate the pad.
6, returned goods should be stored and labeled separately. To find out the reason, timely processing. Due to quality problems and return of medicines with the consent of the health administrative department rework, must be re-inspected and passed before returning to stock. Returned goods should be recorded (including the return unit, date, product name, specifications, quantity, reasons for return, inspection results, date of processing and processing, etc.) and kept for two years.
7, handling and stacking should strictly comply with the requirements of the drug packaging labeling, safe operation, to prevent barbaric loading and unloading.
(E) on the factory direct extraction of drugs should pay attention to the same variety of timely rotation with the inventory, the national reserves of drugs and drugs stored in the external warehouse timely rotation and renewal.
(F) to implement the "first in, first out", "recent first out" and "variable first out", according to the principle of batch number out of the warehouse. Drugs out of the warehouse registered production lot number or year, month, day, expiration date and storage year, month, day. To put a good drug out of storage inspection and issuance of customs, deterioration and expiration of the drug is strictly prohibited shipments.
(VII) the pharmaceutical warehouses, where the storage area of more than 3,000m, should be established to maintain a professional organization, less than 3,000m of the warehouse should be set up full-time maintenance staff.
(viii) the task of drug conservation work
1, guide the custodian of the scientific storage of drugs.
2, check whether the storage conditions of the stock of drugs meet the requirements, with the custodian of his inter-temperature and humidity management, timely adjustment of inventory conditions.
3, the inventory of drugs regularly cycle quality sampling, cycle of sampling is generally a quarter, perishable drugs to shorten the sampling cycle.
4, the problems found in the spot check, put forward processing advice and improve conservation measures. Cooperate with the custodian of the problematic varieties of necessary organization.
5, according to the seasonal climate changes, the preparation of drug inspection program and conservation work plan, listing the key conservation varieties, and be implemented.
6, the establishment of drug conservation files.
7, the key varieties to carry out sampling observation, to examine the causes of change and the law, to guide the rational inventory, improve the level of custody and promote the pharmaceutical factory to improve product quality to provide information.
8, to carry out conservation of scientific research, and gradually make the warehouse storage and maintenance of scientific and modern.